查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1620439

护理点传染病检测市场机会、成长动力、产业趋势分析与预测 2024 - 2032 年

Point of Care Infectious Disease Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 137 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球护理点传染病检测市场价值为 32 亿美元，预计 2024 年至 2032 年将以 6.9% 的年复合成长率(CAGR) 增长。现场进行测试，可快速提供结果，有助于立即做出临床决策，而无需集中实验室。推动POC传染病检测市场扩大的主要因素之一是全球传染病负担不断上升。新病原体的出现、先前受到控制的疾病的死灰復燃以及抗菌素抗药性日益严重的威胁，都凸显了对快速、准确的诊断解决方案的迫切需求。流感、爱滋病毒、肝炎和结核病等疾病持续对全球健康构成重大挑战，进一步增加了对 POC 检测的需求。

技术进步在加速 POC 传染病检测的采用方面发挥着至关重要的作用。设备小型化、数位平台整合以及快速分子测试的发展等方面的创新显着提高了这些诊断的便携性、准确性和速度。具有即时数据共享功能的自动化设备正在改变现场检测的效率，使其在传统实验室访问可能受到限制的偏远或资源有限的环境中非常有价值。此外，POC 测试提供的现场结果的便利性越来越受到医疗保健提供者和患者的青睐，因为它可以带来更有效的患者管理和更好的健康结果。

这对于管理传染病尤其重要，因为及时诊断可以显着影响治疗决策并有助于控制感染的传播。随着全球医疗保健产业更加重视早期检测和快速治疗，POC传染病检测市场必将持续成长。这种成长得到了对改善服务欠缺地区的医疗保健服务的日益关注，以及旨在提高测试准确性和降低成本的持续投资研发的进一步支持。总体而言，不断增长的医疗保健需求、技术创新以及对快速、可操作的诊断资讯的需求相结合，使即时传染病检测市场在未来几年持续扩张。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 32亿美元
预测值 59 亿美元
复合年增长率 6.9%

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 传染病病率上升
      • 即时检测设备的技术进步
      • 人们对现场检测的意识不断增强
    • 产业陷阱与挑战
      • POC测试开发成本高
      • 对准确性和可靠性的担忧
  • 成长潜力分析
  • 监管环境
  • 技术景观
    • 核心技术
    • 邻近技术
  • 未来市场趋势
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

  • 主要趋势
  • 试剂盒和试剂
  • 仪器仪表

第 6 章：市场估计与预测：按技术划分，2021 - 2032 年

  • 主要趋势
  • 分子诊断
  • 侧流免疫分析
  • 凝集试验
  • 流通测试/免疫浓度测定
  • 其他技术

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 热带疾病
  • 肝臟疾病
  • 呼吸系统疾病
  • 医院相关感染
  • 性健康障碍
  • 其他应用

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院
  • 诊断中心
  • 研究和学术机构
  • 家庭护理设置
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Biomerieux
  • Bio-Rad Laboratories
  • Cardinal Health
  • Chembio Diagnostics
  • Danaher Corporation
  • F. Hoffmann-La Roche
  • OJ-Bio
  • QuidelOrtho Corporation
  • Siemens Healthineers
  • Trinity Biotech
  • Trivitron Healthcare
简介目录
Product Code: 11938

The Global Point Of Care Infectious Disease Testing Market was valued at USD 3.2 billion in 2023 and is anticipated to grow at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2032. Point-of-care infectious disease testing refers to diagnostic tests performed near or at the site of patient care, providing rapid results that facilitate immediate clinical decision-making, without the need for centralized laboratories. One of the main factors driving the expansion of the POC infectious disease testing market is the rising global burden of infectious diseases. The emergence of new pathogens, the resurgence of diseases that were previously under control, and the increasing threat of antimicrobial resistance underscore the critical need for rapid and accurate diagnostic solutions. Diseases such as influenza, HIV, hepatitis, and tuberculosis continue to pose significant health challenges worldwide, further boosting the demand for POC testing.

Technological advancements are playing a crucial role in accelerating the adoption of POC infectious disease testing. Innovations in device miniaturization, the integration of digital platforms, and the development of rapid molecular testing have significantly improved the portability, accuracy, and speed of these diagnostics. Automated devices with real-time data-sharing capabilities are transforming the efficiency of point-of-care testing, making them highly valuable in remote or resource-constrained settings where access to traditional laboratories may be limited. Furthermore, the convenience of on-the-spot results provided by POC tests is increasingly favored by healthcare providers and patients alike, as it leads to more efficient patient management and better health outcomes.

This is particularly important in managing infectious diseases where timely diagnosis can significantly impact treatment decisions and help control the spread of infections. With the global healthcare industry placing a stronger emphasis on early detection and rapid treatment, the POC infectious disease testing market is set to experience sustained growth. This growth is further supported by an increasing focus on improving healthcare access in underserved regions, as well as ongoing investments in research and development aimed at enhancing test accuracy and reducing costs. Overall, the combination of rising healthcare needs, technological innovation, and demand for quick, actionable diagnostic information positions the point-of-care infectious disease testing market for continued expansion in the coming years.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$3.2 Billion
Forecast Value$5.9 Billion
CAGR6.9%

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of infectious diseases
      • 3.2.1.2 Technological advancements in point of care testing devices
      • 3.2.1.3 Growing awareness among people for point of care testing
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High development cost of POC tests
      • 3.2.2.2 Concerns about accuracy and reliability
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Kits and reagents
  • 5.3 Instruments

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Molecular diagnostics
  • 6.3 Lateral flow immunoassay
  • 6.4 Agglutination test
  • 6.5 Flow-through Test/Immunoconcentration assay
  • 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Tropical diseases
  • 7.3 Liver diseases
  • 7.4 Respiratory diseases
  • 7.5 Hospital associated infections
  • 7.6 Sexual health disorders
  • 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Diagnostic centers
  • 8.4 Research and academic institutes
  • 8.5 Homecare settings
  • 8.6 Others end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Becton, Dickinson and Company
  • 10.3 Biomerieux
  • 10.4 Bio-Rad Laboratories
  • 10.5 Cardinal Health
  • 10.6 Chembio Diagnostics
  • 10.7 Danaher Corporation
  • 10.8 F. Hoffmann-La Roche
  • 10.9 OJ-Bio
  • 10.10 QuidelOrtho Corporation
  • 10.11 Siemens Healthineers
  • 10.12 Trinity Biotech
  • 10.13 Trivitron Healthcare